Berkshire Biomedical Announces Equity Crowdfunding Campaign

Berkshire Biomedical Today Launched Its First Public Investment Campaign to Support the Advancement of Its Revolutionary COPA™ Technology

, /PRNewswire/ -- Berkshire Biomedical Corporation ("Berkshire" or the "Company"), focused on developing its proprietary drug dispensing technology to enhance patient wellness, today announced the launch of an equity crowdfunding campaign on StartEngine. This campaign offers potential investors the unique opportunity to invest in, and own, a part of a company dedicated to revolutionizing patient administered personalized medication delivery.

The Company's Computerized Oral Prescription Administration System (COPA™) is a novel, oral liquid dispensing system specifically designed to deliver accurate and precise doses of controlled and non-controlled prescription medications to only an Authenticated Intended User (AIU™), upon confirmation of dual biometric identifications, (fingerprint and dentition), with the goal of enhancing patient wellness and providing remote monitoring.

"We are incredibly excited to open this equity crowdfunding opportunity for individual investors to become a part of Berkshire's journey," stated John Timberlake, Chief Executive Officer of Berkshire. "Our goal is to enhance patient wellness by leveraging technology to improve medical outcomes. We believe that our proprietary, cloud-based, healthcare-enabled COPA device has the potential to dramatically increase the number of people with Opioid Use Disorder (OUD) receiving medication treatment, which is currently estimated to be just 20% of the 5.7 million people with OUD. In addition, we believe that COPA also has utility and value to help those with other chronic illnesses including those suffering from chronic pain and other CNS diseases. Our equity crowdfunding campaign on StartEngine provides the opportunity for any interested parties to join us in shaping the future of personalized medication delivery."

The equity crowdfunding campaign is now live on StartEngine, offering investors the chance to be a part of Berkshire's growth and innovation. Details of the offering can be found at StartEngine's Berkshire Offering Page.

About Berkshire Biomedical Corporation

Berkshire Biomedical Corporation is a privately held medical device company. Berkshire is pioneering the use of biometric technologies, combined with encrypted HIPAA compliant cloud-based and healthcare provider-enabled remote management systems, to provide precise and accurate personalized medication delivery to only the Authenticated Intended User (AIU).

The Company's lead product under development, the Computerized Oral Prescription Administration System (COPA), is a hand-held, automated, personalized oral liquid dispensing system designed and intended to deliver controlled and non-controlled liquid oral medications to only the AIU upon confirmation of dual biometric identification (fingerprint and dentition).

Upon receiving regulatory authorization, the Company intends to initially seek opportunities to leverage COPA in the delivery and remote management of oral liquid medication methadone, for Medication Use for Opioid Use Disorder treatment and subsequently for the delivery of controlled medications for the treatment of pain, as those patients have the greatest need for the benefits of COPA's features.

As previously announced, the Company is developing COPA with the support of a $2.0 million Fast-Track Small Business Innovation Research grant from the National Institute of Drug Abuse of the National Institutes of Health under award number R44DA057185.

In the future, the Company will look to expand COPA usage into a broader set of drug therapeutics, possible clinical applications, as well as with companies that utilize and commercialize data analytics provided by electronic devices to improve outcomes and reduce risk.

Additional information about Berkshire Biomedical and the COPA System can be found at www.berkbiomed.com. The COPA System is currently under development, has NOT been reviewed by the U.S. Food and Drug Administration and is not available for commercial sale.

Disclaimer: Research reported in this communication was supported by the National Institute on Drug Abuse of the National Institutes of Health under award number R44DA057185. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

This Reg CF offering is made available through StartEngine Primary LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

CONTACT:

Berkshire Biomedical Corporation
[email protected]

Melody Carey
Founder, President, and CEO
Rx Communications Group, LLC
[email protected]

SOURCE Berkshire Biomedical Corporation